RADNOR, Pa., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on November 3, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award coveri
Mineralys Therapeutics Inc (MLYS) showcased robust lorundrostat efficacy and advanced commercial preparations while reporting a widened net loss ahead of its December PDUFA date.
Lorundrostat’s Phase 2 Explore-CKD data is now in a top kidney journal, giving Mineralys Therapeutics (MLYS) a clearer clinical story focused on blood pressure and urinary protein reductions in chronic kidney disease patients. Despite the Kidney International publication and a series of lorundrostat updates, Mineralys Therapeutics’ share price return has been weak, with the stock down 52.39% year to date and 37.01% over 90 days. At the same time, a very large 3 year total shareholder return...
Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.
Detailed price information for Mineralys Therapeutics Inc (MLYS-Q) from The Globe and Mail including charting and trades.
2026-10-09. The following slide deck was published by Mineralys Therapeutics, Inc.
Why the latest lorundrostat data matters for Mineralys Therapeutics investors Mineralys Therapeutics (MLYS) is back on watch after the company flagged that long term efficacy and safety results from its Transform-HTN extension study of lorundrostat will feature in a late breaking session at the American Heart Association Scientific Sessions 2026. The latest lorundrostat update comes after a choppy stretch for Mineralys Therapeutics, with the share price falling 8.65% over the past week and...
RADNOR, Pa., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on September 21, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award cov
RADNOR, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on September 8, 2026, the Compensation Committee of Mineralys’ Board of Directors granted inducement stock option awards coveri
RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines...
This is the newest page. Registered accounts read further back.